Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 690 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Patient Guide in Prostate Cancer Now Available Also in German December 18, 2025 Pine Trees or COVID? September 2, 2020 Finding Hope in the New Year During COVID-19 and Cancer January 6, 2021 Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 Load more HOT NEWS Cancer in children and young people: how far we’ve come Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... What Is Mindfulness and How Can It Help People With Cancer? Breast Cancer Patient Given 2 Years to Live is Now a...
